1. Gratz KL, Dixon-Gordon KL, Chapman AL, Tull MT. Diagnosis and characterization of dsm-5 nonsuicidal self-injury disorder using the Clinician-Administered Nonsuicidal Self-Injury Disorder Index. Assessment. 2015; 22(5): 527-539. https://doi.org/10.1177/1073191114565878
2.
World Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11) [Internet]. Geneva: WHO; 2019/2021 [access 2023 Dec 14]. Available from: https://icd.who.int/browse11
3.
American Psychiatric Association. Desk reference to the diagnostic criteria from DSM-5. Arlington, VA: American Psychiatric Association; 2013.
4.
Ammmerman BA, Hong M, Sorgi K, Park Y, Jacobucci R, McCloskey MS. An examination of individual forms of nonsuicidal self-injury. Psychiatry Res. 2019; 278: 268-274. https://doi.org/10.1016/j.psychres.2019.06.029
5.
Zetterqvist M, Jonsson LS, Landberg Å, Svedin CG. A potential increase in adolescent nonsuicidal self-injury during Covid-19: a comparison of data from three different time points during 2011-2021. Psychiatry Res. 2021; 305: 114208. https://doi.org/10.1016/j.psychres.2021.114208
6.
Xiao Q, Song X, Huang L, Hou D, Huang X. Global prevalence and characteristics of non-suicidal self-injury between 2010 and 2021 among a non-clinical sample of adolescents: a meta-analysis. Front Psychiatry. 2022; 13: 912441. https://doi.org/10.3389/fpsyt.2022.912441
7.
Wolff J, Frazier EA, Esposito-Smythers C, Burke T, Sloan E, Spirito A. Cognitive and social factors associated with NSSI and suicide attempts in psychiatrically hospitalized adolescents. J Abnorm Child Psychol. 2013; 41(6): 1005-1013. https://doi.org/10.1007/s10802-013-9743-y
8.
Nesi J, Burke TA, Lawrence HR, MacPherson HA, Spirito A, Wolff JC. Online self-injury activities among psychiatrically hospitalized adolescents: prevalence, functions, and perceived consequences. Res Child Adolesc Psychopathol. 2021; 49(4): 519-531. https://doi.org/10.1007/s10802-020-00734-4
9.
Makowska I, Gmitrowicz A. Non-suicidal self-injury vs. suicidal behaviour disorder. Psychiatr i Psychol Klin. 2018; 18(2): 173-179 (in Polish). https://doi.org/10.15557/PiPK.2018.0020
10.
Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019; 4: 5. https://doi.org/10.1186/s41073-019-0064-8
11.
Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study [published correction appears in Am J Psychiatry. 2019 Sep 1; 176(9): 764]. Am J Psychiatry. 2009; 166(4): 418-426. https://doi.org/10.1176/appi.ajp.2008.08070976
12.
Cato V, Holländare F, Nordenskjöld A, Sellin T. Association between benzodiazepines and suicide risk: a matched case-control study. BMC Psychiatry. 2019; 19(1): 317. https://doi.org/10.1186/s12888-019-2312-3
13.
Tournier M, Bénard-Laribière A, Jollant F, Hucteau E, Diop PY, Jarne-Munoz A, et al. Risk of suicide attempt and suicide associated with benzodiazepine: A nationwide case crossover study. Acta Psychiatr Scand. 2023; 148(3): 233-241. https://doi.org/10.1111/acps.13582
14.
Plener PL, Brunner R, Fegert JM, Groschwitz RC, In-Albon T, Kaess M, et al. Treating nonsuicidal self-injury (NSSI) in adolescents: consensus based German guidelines. Child Adolesc Psychiatry Ment Health. 2016; 10: 46. https://doi.org/10.1186/s13034-016-0134-3
15.
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020; 11: 595584. https://doi.org/10.3389/fpsyt.2020.595584
16.
www.rejestrymedyczne.ezdrowie.gov.pl [Internet]. Warsaw: Ministry of Health; 2021 Apr. [Product characteristics of Hydroxyzinum VP] [access 2023 Dec 29]. Available from: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/3001/characteristic (in Polish).
17.
Saito E, Eng S, Grosso C, Ozinci Z, Van Meter A. Pro re nata medication use in acute care adolescent psychiatric unit. J Child Adolesc Psychopharmacol. 2020; 30(4): 250-260. https://doi.org/10.1089/cap.2019.0131
18.
Vitiello B, Ricciuti AJ, Behar D. P.R.N. medications in child state hospital inpatients: a pilot placebo-controlled study. J Clin Psychiatry. 1987; 48(9): 351-354.
19.
Hoffmann JA, Pergjika A, Konicek CE, Reynolds SL. Pharmacologic management of acute agitation in youth in the emergency department. Pediatr Emerg Care. 2021; 37(8): 417-422. https://doi.org/10.1097/PEC.0000000000002510
20.
Gerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM. Best Practices for Evaluation and Treatment of Agitated Children and Adolescents (BETA) in the emergency department: consensus statement of the American Association for Emergency Psychiatry [published correction appears in West J Emerg Med. 2019 May; 20(3): 537 / published correction appears in West J Emerg Med. 2019 Jul; 20(4): 688-689]. West J Emerg Med. 2019; 20(2): 409-418. https://doi.org/10.5811/westjem.2019.1.41344
21.
Ercan ES, Ardiç ÜA, Kandulu R, Yektas C. Zuclopenthixol acetate treatment in children with bipolar disorder and severe aggression. J Clin Psychopharmacol. 2011; 31(3): 397-398. https://doi.org/10.1097/JCP.0b013e3182192e86
22.
Curry A, Malas N, Mroczkowski M, Hong V, Nordstrom K, Terrell C. Updates in the assessment and management of agitation. Focus (Am Psychiatr Publ). 2023; 21(1): 35-45. https://doi.org/10.1176/appi.focus.20220064
23.
Naguy A. Clonidine use in psychiatry: panacea or panache. Pharmacology. 2016; 98(1-2): 87-92. https://doi.org/10.1159/000446441
24.
Neuchat EE, Bocklud BE, Kingsley K, Barham WT, Luther PM, Ahmadzadeh S, et al. The role of alpha-2 agonists for attention deficit hyperactivity disorder in children: a review. Neurol Int. 2023; 15(2): 697-707. https://doi.org/10.3390/neurolint15020043
25.
Philipsen A, Richter H, Schmahl C, Peters J, Rüsch N, Bohus M, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry. 2004; 65(10): 1414-1419. https://doi.org/10.4088/jcp.v65n1018
26.
Ciccone CD. Hydroxyzine. Davis's Drug Guide for rehabilitation professionals. [Internet]. Philadelphia: Davis Company; 2016 [access 2024 Feb 29]. Available from: https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139013808
27.
Dionne RA, Trapp LD. Oral and rectal sedation. In: Dionne RA, Phero JC, Becker DE, editors. Management of pain & anxiety in the dental office. Philadelphia: W.B. Saunders; 2002; p. 225-234. https://doi.org/10.1016/B0-7216-7278-7/50019-8
28.
Patel DR, Feucht C, Brown K, Ramsay J. Pharmacological treatment of anxiety disorders in children and adolescents: a review for practitioners. Transl Pediatr. 2018; 7(1): 23-35. https://doi.org/10.21037/TP.2017.08.05
29.
Chun TH, Mace SE, Katz ER, American Academy of Pediatrics, Committee on Pediatric Emergency Medicine, American College of Emergency Physicians, et al. Evaluation and management of children and adolescents with acute mental health or behavioral problems. Part I: Common clinical challenges of patients with mental health and/or behavioral emergencies. Pediatrics. 2016; 138(3): e20161570. https://doi.org/10.1542/peds.2016-1570
30.
Eggart V, Cordier S, Hasan A, Wagner E. Psychotropic drugs for the treatment of non-suicidal self-injury in children and adolescents: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2022; 272(8): 1559-1568. https://doi.org/10.1007/s00406-022-01385-w
31.
National Institute for Health and Care Excellence. Self-harm: assessment, management and preventing recurrence. NICE guideline [Internet]. Manchester: National Institute for Health and Care Excellence; 2022 Sep [access 2023 Dec 14]. Available from: https://www.nice.org.uk/guidance/ng225/resources/selfharm-assessment-management-and-preventing-recurrence-pdf-66143837346757
32.
Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacology Bulletin. 1995; 31(4): 773-777. https://doi.org/10.1097/yic.0000000000000004
33.
Wollweber B, Keck ME, Schmidt U. Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases. Ther Adv Psychopharmacol. 2015; 5(4): 208-213. https://doi.org/10.1177/2045125315585652
34.
Popova NK, Tsybko AS, Naumenko VS. The implication of 5-HT receptor family members in aggression, depression and suicide: similarity and difference. Int J Mol Sci. 2022; 23(15): 8814. https://doi.org/10.3390/ijms23158814
35.
Libal G, Plener PL, Ludolph AG, Fegert JM. Ziprasidone as a weight-neutral alternative in the treatment of self-injurious behavior in adolescent females. Child and Adolescent Psychopharmacology News. 2005; 10(4): 1-6. https://doi.org/101521/capn20051041
36.
Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006; 163(5): 833-838. https://doi.org/10.1176/ajp.2006.163.5.833
37.
Good CR. Adjunctive quetiapine targets self-harm behaviors in adolescent females with major depressive disorder. J Child Adolesc Psychopharmacol. 2006; 16(3): 235-236. https://doi.org/10.1089/cap.2006.16.235
38.
Cohen SA, Ihrig K, Lott RS, Kerrick JM. Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord. 1998; 28(3): 229-233. https://doi.org/10.1023/a:1026069421988
39.
Hough DW. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder. J Clin Psychiatry. 2001; 62(4): 296-297. https://doi.org/10.4088/jcp.v62n0413d
40.
Hammock R, Levine WR, Schroeder SR. Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation. J Autism Dev Disord. 2001; 31(1): 109-113. https://doi.org/10.1023/a:1005626100084
41.
Yonezawa K, Kanegae S, Ozawa H. Antipsychotics/neuroleptics: pharmacology and biochemistry. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. NeuroPsychopharmacotherapy. Cham: Springer; 2022. https://doi.org/10.1007/978-3-030-62059-2_52
42.
Rogalski JK, Subdys A, Gawlik-Kotelnicka OE. The development of the metabolic-associated fatty liver disease during pharmacotherapy of mental disorders – a review. Curr Probl Psychiatry. 2022; 23(3): 128-143. https://doi.org/10.2478/cpp-2022-0013
43.
Stoffers-Winterling JM, Storebø OJ, Pereira Ribeiro J, Kongerslev MT, Völlm BA, Mattivi JT, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022; 11(11): CD012956. https://doi.org/10.1002/14651858.CD012956.pub2
44.
Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, et al. Pharmacological interventions for self-harm in adults. Cochrane Database Syst Rev. 2021; 1(1): CD013669. https://doi.org/10.1002/14651858.CD013669.pub2
45.
National Collaborating Centre for Mental Health (UK). Borderline personality disorder: treatment and management. Leicester: British Psychological Society; 2009.
46.
Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord. 1998; 51(3): 333-343. https://doi.org/10.1016/s0165-0327(99)00007-5
47.
Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry. 1986; 143(4): 519-522. https://doi.org/10.1176/ajp.143.4.519
48.
Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003; 28(6): 1186-1197. https://doi.org/10.1038/sj.npp.1300153
49.
Raju Sagiraju HK, Wang CP, Amuan ME, Van Cott AC, Altalib HH, Pugh MJV. Antiepileptic drugs and suicide-related behavior: is it the drug or comorbidity?. Neurol Clin Pract. 2018; 8(4): 331-339. https://doi.org/10.1212/CPJ.0000000000000489
50.
Hayes JF, Pitman A, Marston L, Walters K, Geddes JR, King M, et al. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study. JAMA Psychiatry. 2016; 73(6): 630-637. https://doi.org/10.1001/jamapsychiatry.2016.0432
51.
Masters KJ. Anti-suicidal and self-harm properties of lithium carbonate. CNS Spectr. 2008; 13(2): 109-110. https://doi.org/10.1017/s1092852900016230
52.
Katz IR, Rogers MP, Lew R, Thwin SS, Doros G, Ahearn E, et al. Lithium treatment in the prevention of repeat suicide-related outcomes in veterans with major depression or bipolar disorder: a randomized clinical trial. JAMA Psychiatry. 2022; 79(1): 24-32. https://doi.org/10.1001/jamapsychiatry.2021.3170
53.
Baldessarini RJ, Tondo L. Testing for antisuicidal effects of lithium treatment. JAMA Psychiatry. 2022; 79(1): 9-10. https://doi.org/10.1001/jamapsychiatry.2021.2992
54.
Blasco-Fontecilla H, Fernández-Fernández R, Colino L, Fajardo L, Perteguer-Barrio R, de Leon J. The addictive model of self-harming (non-suicidal and suicidal) behavior. Front Psychiatry. 2016; 7: 8. https://doi.org/10.3389/fpsyt.2016.00008
55.
Störkel LM, Karabatsiakis A, Hepp J, Kolassa IT, Schmahl C, Niedtfeld I. Salivary beta-endorphin in nonsuicidal self-injury: an ambulatory assessment study. Neuropsychopharmacology. 2021; 46(7): 1357-1363. https://doi.org/10.1038/s41386-020-00914-2
56.
Worley J. Self-injury as an addictive disorder. J Psychosoc Nurs Ment Health Serv. 2020; 58(6): 13-16. https://doi.org/10.3928/02793695-20200513-03
57.
Toljan K, Vrooman B. Low-dose Naltrexone (LDN) – review of therapeutic utilization. Med Sci (Basel). 2018; 6(4): 82. https://doi.org/10.3390/medsci6040082
58.
Singh D, Saadabadi A. Naltrexone. [Internet]. StatPearls; 2023 May [access 2023 Dec 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534811/
59.
Bieńkowski P. [Pharmacological features of naltrexone and its use in the treatment of alcohol dependence]. Psychiatr Pol. 2013; 47(1): 117-126 (in Polish).
60.
Mouaffak F, Leite C, Hamzaoui S, Benyamina A, Laqueille X, Kebir O. Naltrexone in the treatment of broadly defined behavioral addictions: a review and meta-analysis of randomized controlled trials. Eur Addict Res. 2017; 23(4): 204-210. https://doi.org/10.1159/000480539
61.
White T, Schultz SK. Naltrexone treatment for a 3-year-old boy with self-injurious behavior. Am J Psychiatry. 2000; 157(10): 1574-1582. https://doi.org/10.1176/appi.ajp.157.10.1574
62.
Kotadia H, Rawat K, Maheshwari A. Role of Naltrexone in treatment of refractory self-injurious behavior in a child with intellectual disability: a case report. Journal of Indian Association for Child and Adolescent Mental Health. 2022; 18(1): 104-106. https://doi.org/10.1177/09731342221096410
63.
Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry. 1996; 57(6): 233-237.
64.
Sonne S, Rubey R, Brady K, Malcolm R, Morris T. Naltrexone treatment of self-injurious thoughts and behaviors. J Nerv Ment Dis. 1996; 184(3): 192-195. https://doi.org/10.1097/00005053-199603000-00011
65.
Campbell M, Overall JE, Small AM, Sokol MS, Spencer EK, Adams P, et al. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry. 1989; 28(2): 200-206. https://doi.org/10.1097/00004583-198903000-00009
66.
Norelli LJ, Smith HS, Sher L, Blackwood TA. Buprenorphine in the treatment of non-suicidal self-injury: a case series and discussion of the literature. Int J Adolesc Med Health. 2013; 25(3): 323-330. https://doi.org/10.1515/ijamh-2013-0069
67.
Lee DK, Lipner SR. The potential of N-Acetylcysteine for treatment of trichotillomania, excoriation disorder, onychophagia, and onychotillomania: an updated literature review. Int J Environ Res Public Health. 2022; 19(11): 6370. https://doi.org/10.3390/ijerph19116370
68.
Guerdjikova AI, Gwizdowski IS, McElroy SL, McCullumsmith C, Suppes P. Treating nonsuicidal self-injury. Curr Treat Options Psych. 2014; 1: 325-334. https://doi.org/10.1007/s40501-014-0028-z
69.
Hudon A, Proulx S. Topiramate-induced suicidal ideation and olfactory hallucinations: a case report. Reports. 2022; 5(2):13. https://doi.org/10.3390/reports5020013
Copyright: © 2024 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
